Ser324

Site Information
sSNHSARsPFEGAVT SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3178689

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 )
Disease tissue studied:	breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , cervical cancer ( 11 ) , cervical adenocarcinoma ( 11 ) , leukemia ( 15 ) , chronic myelogenous leukemia ( 15 ) , lung cancer ( 6 , 9 ) , non-small cell lung cancer ( 6 ) , lymphoma ( 4 ) , Burkitt's lymphoma ( 4 ) , follicular lymphoma ( 4 ) , mantle cell lymphoma ( 4 ) , ovarian cancer ( 3 )
Relevant cell line - cell type - tissue:	A498 (renal) ( 10 ) , BJAB (B lymphocyte) ( 4 ) , breast ( 1 , 3 ) , CL1-0 (pulmonary) ( 9 ) , CL1-1 (pulmonary) ( 9 ) , CL1-2 (pulmonary) ( 9 ) , CL1-5 (pulmonary) ( 9 ) , FL-318 (B lymphocyte) ( 4 ) , H2077 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HeLa (cervical) ( 2 , 8 , 13 ) , HeLa S3 (cervical) ( 11 ) , Jurkat (T lymphocyte) ( 5 , 12 ) , K562 (erythroid) ( 14 , 15 ) , LOU-NH91 (squamous) ( 6 ) , NCI-H460 (pulmonary) ( 6 ) , ovary ( 3 ) , Raji (B lymphocyte) ( 4 ) , REC-1 (B lymphocyte) ( 4 )

Upstream Regulation
Treatments:	metastatic potential ( 9 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
3	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
4	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
5	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
6	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
7	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
8	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
9	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
10	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
11	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
12	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
13	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
14	Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
15	Stokes M (2008) CST Curation Set: 4389; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info